Skip to main content
NASDAQ:LIVN

LivaNova Competitors

$84.05
+0.58 (+0.69 %)
(As of 05/13/2021 02:39 PM ET)
Add
Compare
Today's Range
$83.14
$84.92
50-Day Range
$72.40
$86.34
52-Week Range
$41.07
$90.25
Volume4,742 shs
Average Volume467,641 shs
Market Capitalization$4.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8

Competitors

LivaNova (NASDAQ:LIVN) Vs. VAR, MASI, CNMD, INMD, OM, and BLFS

Should you be buying LIVN stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to LivaNova, including Varian Medical Systems (VAR), Masimo (MASI), CONMED (CNMD), InMode (INMD), Outset Medical (OM), and BioLife Solutions (BLFS).

Varian Medical Systems (NYSE:VAR) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Varian Medical Systems and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Varian Medical Systems8.50%18.45%8.08%
LivaNova-21.88%5.55%3.07%

Analyst Ratings

This is a summary of current ratings for Varian Medical Systems and LivaNova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Varian Medical Systems15001.83
LivaNova02202.50

Varian Medical Systems currently has a consensus price target of $177.70, indicating a potential upside of 0.36%. LivaNova has a consensus price target of $87.75, indicating a potential upside of 4.96%. Given LivaNova's stronger consensus rating and higher probable upside, analysts plainly believe LivaNova is more favorable than Varian Medical Systems.

Insider and Institutional Ownership

87.0% of Varian Medical Systems shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 0.8% of Varian Medical Systems shares are held by insiders. Comparatively, 0.5% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Varian Medical Systems and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29
LivaNova$1.08 billion3.79$-155,180,000.00$3.0827.29

Varian Medical Systems has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Varian Medical Systems has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Summary

Varian Medical Systems beats LivaNova on 10 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Masimo and LivaNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million12.84$196.22 million$3.2267.97
LivaNova$1.08 billion3.79$-155,180,000.00$3.0827.29

Masimo has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

81.6% of Masimo shares are held by institutional investors. Comparatively, 89.1% of LivaNova shares are held by institutional investors. 11.5% of Masimo shares are held by insiders. Comparatively, 0.5% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Masimo and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
LivaNova-21.88%5.55%3.07%

Risk and Volatility

Masimo has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Masimo and LivaNova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02402.67
LivaNova02202.50

Masimo currently has a consensus price target of $291.50, suggesting a potential upside of 33.97%. LivaNova has a consensus price target of $87.75, suggesting a potential upside of 4.96%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than LivaNova.

Summary

Masimo beats LivaNova on 12 of the 14 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and CONMED (NYSE:CNMD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Profitability

This table compares LivaNova and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
CONMED0.04%9.48%3.75%

Risk and Volatility

LivaNova has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. 0.5% of LivaNova shares are held by insiders. Comparatively, 5.4% of CONMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for LivaNova and CONMED, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova02202.50
CONMED01202.67

LivaNova presently has a consensus price target of $87.75, suggesting a potential upside of 4.96%. CONMED has a consensus price target of $117.3333, suggesting a potential downside of 16.09%. Given LivaNova's higher probable upside, analysts clearly believe LivaNova is more favorable than CONMED.

Earnings and Valuation

This table compares LivaNova and CONMED's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.79$-155,180,000.00$3.0827.29
CONMED$955.10 million4.29$28.62 million$2.6453.41

CONMED has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats LivaNova on 8 of the 13 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and InMode (NASDAQ:INMD) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares LivaNova and InMode's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
InMode32.57%28.56%24.14%

Earnings & Valuation

This table compares LivaNova and InMode's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.79$-155,180,000.00$3.0827.29
InMode$156.36 million14.17$61.15 million$1.6043.32

InMode has lower revenue, but higher earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of LivaNova shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for LivaNova and InMode, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova02202.50
InMode00403.00

LivaNova currently has a consensus price target of $87.75, suggesting a potential upside of 4.96%. InMode has a consensus price target of $80.25, suggesting a potential upside of 15.48%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than LivaNova.

Summary

InMode beats LivaNova on 10 of the 14 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Outset Medical (NASDAQ:OM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares LivaNova and Outset Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.79$-155,180,000.00$3.0827.29
Outset MedicalN/AN/AN/AN/AN/A

Outset Medical has lower revenue, but higher earnings than LivaNova.

Profitability

This table compares LivaNova and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
Outset MedicalN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and target prices for LivaNova and Outset Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova02202.50
Outset Medical03502.63

LivaNova currently has a consensus target price of $87.75, suggesting a potential upside of 4.96%. Outset Medical has a consensus target price of $58.20, suggesting a potential upside of 33.61%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than LivaNova.

Insider and Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. Comparatively, 84.6% of Outset Medical shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

LivaNova beats Outset Medical on 5 of the 9 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Institutional and Insider Ownership

67.7% of BioLife Solutions shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 22.3% of BioLife Solutions shares are owned by company insiders. Comparatively, 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

BioLife Solutions has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Valuation & Earnings

This table compares BioLife Solutions and LivaNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$27.37 million36.37$-1,660,000.00$0.08369.00
LivaNova$1.08 billion3.79$-155,180,000.00$3.0827.29

BioLife Solutions has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioLife Solutions and LivaNova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioLife Solutions01902.90
LivaNova02202.50

BioLife Solutions currently has a consensus price target of $46.6667, suggesting a potential upside of 58.25%. LivaNova has a consensus price target of $87.75, suggesting a potential upside of 4.96%. Given BioLife Solutions' stronger consensus rating and higher probable upside, equities research analysts plainly believe BioLife Solutions is more favorable than LivaNova.

Profitability

This table compares BioLife Solutions and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioLife Solutions12.67%0.53%0.43%
LivaNova-21.88%5.55%3.07%

Summary

BioLife Solutions beats LivaNova on 8 of the 14 factors compared between the two stocks.


LivaNova Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07+0.0%$16.26 billion$3.17 billion60.43
Masimo logo
MASI
Masimo
1.8$218.86+1.8%$11.82 billion$937.84 million56.85
CONMED logo
CNMD
CONMED
1.8$141.00+2.8%$3.99 billion$955.10 million-3,525.00
InMode logo
INMD
InMode
1.7$69.31+1.9%$2.26 billion$156.36 million49.86Analyst Report
Outset Medical logo
OM
Outset Medical
1.5$42.33+6.4%$2.07 billionN/A0.00Analyst Report
News Coverage
Gap Up
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$29.52+2.9%$1.02 billion$27.37 million-40.44Unusual Options Activity
NTUS
Natus Medical
1.1$28.20+2.9%$933.40 million$495.52 million-51.27Earnings Announcement
News Coverage
AxoGen logo
AXGN
AxoGen
1.5$21.05+1.0%$854.09 million$106.71 million-33.41Analyst Report
ViewRay logo
VRAY
ViewRay
1.3$4.97+0.4%$807.08 million$87.78 million-5.58Earnings Announcement
Analyst Upgrade
TransMedics Group logo
TMDX
TransMedics Group
1.6$21.81+3.2%$621.82 million$23.60 million-15.58Analyst Report
Gap Down
Cutera logo
CUTR
Cutera
1.5$29.32+1.4%$529.34 million$181.71 million-16.20
Zynex logo
ZYXI
Zynex
1.8$13.47+3.6%$486.46 million$45.47 million40.82
Edap Tms logo
EDAP
Edap Tms
1.3$6.03+3.8%$208.55 million$50.23 million-100.50Earnings Announcement
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$5.09+25.3%$178.06 million$3.38 million-2.66Unusual Options Activity
News Coverage
IRIDEX logo
IRIX
IRIDEX
1.3$7.12+5.9%$117.82 million$43.45 million-12.95Earnings Announcement
Analyst Report
News Coverage
FONR
FONAR
1.1$17.84+7.1%$108.67 million$85.69 million16.83Upcoming Earnings
News Coverage
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.20+4.1%$98.68 millionN/A0.00Upcoming Earnings
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.00+3.0%$85.78 million$10,000.00-1.09Upcoming Earnings
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$0.98+2.0%$79.72 millionN/A-1.29Analyst Downgrade
electroCore logo
ECOR
electroCore
1.4$1.55+4.5%$78.64 million$2.39 million-1.96Earnings Announcement
Analyst Revision
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$14.26+5.5%$34.87 million$1.50 million-0.82Upcoming Earnings
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.42+3.7%$25.96 million$6.57 million-0.01
Nuwellis logo
CHFS
Nuwellis
1.7$3.74+7.5%$22.58 million$5.51 million-0.08News Coverage
Star Equity logo
STRR
Star Equity
0.1$2.66+3.8%$13.59 million$114.18 million-0.85Upcoming Earnings
News Coverage
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.